UCB Pharma

NICE recommends UCB’s RYSTIGGO▼ (rozanolixizumab) for adults with antibody-positive generalised myasthenia gravis in Final Draft Guidance

Rozanolixizumab, discovered and developed in the UK, has been recommended by NICE as an add on treatment option for eligible adults with antibody-positive generalised myasthenia gravis (gMG) Recommendation represents three firsts: first recommendation for targeted therapy for gMG; first recommendation in myasthenia gravis via the Single Technology Appraisal route; one of the first medicines recommended...
208 Bath Road Slough Berkshire SL1 3WE

+44 (0) 1753 534 655